The Phase II trial will assess the therapy’s safety, tolerability and its activity across various biomarkers in IPF patients.

Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

How much did they smoke? Were they exposed to smoke from others? Were they born prematurely? Did they experience a lot of ...

After surviving a double lung transplant, Craig Kanarick walks Manhattan’s 32-mile perimeter to support PF Warriors and raise ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Pulmonary fibrosis is a growing global health concern with varying epidemiological trends. In Western populations, IPF prevalence ranges from 2 to 29 cases per 100,000 individuals, with incidence ...

According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM ...

Q1 2025 Management View CEO Martine Rothblatt highlighted that United Therapeutics achieved record revenue for the quarter, marking the ninth such achievement in the past 12 quarters. She emphasized ...

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic ...

Introduction Interstitial lung disease (ILD) patients may develop a progressive phenotype usually characterised by ...

After getting ill following a routine bronchoscopy procedure, columnist Sam Kirton learns he has a bacterial infection in his lungs.